Patient Global Impression of Change much or very much improved · people with cancer pain
1 finding from 1 review
Serious adverse events (death) · people with cancer pain
1 finding from 1 review
Other adverse events · people with cancer pain
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Treatment withdrawal · people with cancer pain
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Participants with at least 30% or at least 50% reduction in pain · people with cancer pain
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
PGIC much or very much improved · people with cancer pain
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Mean pain intensity at end of study · people with cancer pain
1 finding from 1 review
Intervention not reported
Pain no worse than mild at one or two weeks (or equivalent) · people with cancer pain
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Mean quality of life or "well‐being" · people with cancer pain
1 finding from 1 review
Intervention not reported
Participant preference · people with cancer pain
1 finding from 1 review
Intervention not reported
Adverse events · people with cancer pain
1 finding from 1 review
Intervention not reported
Serious adverse events · people with cancer pain
1 finding from 1 review
Relapse, drop‐outs classed as relapse, grouped by length of · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in relapse, drop‐outs classed as relapse, grouped by length of compared with placebo (moderate certainty).
3 findings from 1 review
RR 0.98 [0.91, 1.07]
11 studies · 2014 participants
Moderate
RR 0.99 [0.8, 1.23]
1 study · 161 participants
Low
RR 1.07 [0.86, 1.33]
1 study · 132 participants
Moderate
Adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Number of participants receiving transfusion with allogeneic blood: aprotinin vs placebo · children undergoing surgery for scoliosis
It is very uncertain whether the intervention changes number of participants receiving transfusion with allogeneic blood:… (very low certainty).
1 finding from 1 review
Intervention not reported
Mean total blood transfused (mL): aprotinin vs placebo · children undergoing surgery for scoliosis
1 finding from 1 review
Intervention not reported
Mean total blood transfused (mL): tranexamic acid vs placebo · children undergoing surgery for scoliosis
1 finding from 1 review
Intervention not reported
Mean total blood loss (mL): aprotinin vs placebo · children undergoing surgery for scoliosis
1 finding from 1 review